Topical PTH (1-34) is a novel, safe and effective treatment for psoriasis: a randomized self-controlled trial and an open trial.

Holick MF, Chimeh FN, Ray S

The British journal of dermatology1 Aug 2003Cited by 14 (Europe PMC)

PMID12932245DOI10.1046/j.1365-2133.2003.05437.xPepBankPUB-12932245

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In psoriasis, lesion severity improved by 67.3% with PTH versus 17.8% with placebo.
In plain wordsIn patients with psoriasis, lesion severity improved more with PTH than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseGlobal severity score
Study
n = 15
Comparator
Placebo-treated lesion
Outcome group
Skin and hair · Skin and wound
Studied dose
20 microg per 0.1 g twice daily · topical · 2 monthsAs given in this study (human).
Measurements
Severity improvement
67.3%
PTH-treated lesion
Severity improvement
17.8%
Placebo-treated lesion
Source sentences
Summary
There was a 67.3% improvement in the global severity score for the lesion treated with PTH (1-34) compared with the placebo-treated lesion, which only showed a 17.8% improvement.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifteen adult patients with chronic plaque psoriasis who had failed to respond to at least one standard treatment were enrolled in a randomized double-blinded placebo self-controlled trial. The patients topically applied to a 25-cm2 psoriatic lesion 0.1 g of either Novasome A cream or Novasome A cre…
Report a problemFND-1293224505
02HumanRandomized controlled trialEfficacy outcome
In patients with psoriasis, PTH-treated lesions showed marked improvement in scaling.
In plain wordsIn patients with psoriasis, PTH-treated lesions had less scaling.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseLesion scaling
Study
n: not reported in source
Outcome group
Skin and hair · Skin and wound
Studied dose
20 microg per 0.1 g twice daily · topical · 2 monthsAs given in this study (human).
Source sentences
Summary
Psoriatic lesions treated with PTH (1-34) showed marked improvement in scaling, erythema and induration.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifteen adult patients with chronic plaque psoriasis who had failed to respond to at least one standard treatment were enrolled in a randomized double-blinded placebo self-controlled trial. The patients topically applied to a 25-cm2 psoriatic lesion 0.1 g of either Novasome A cream or Novasome A cre…
Report a problemFND-1293224502
03HumanRandomized controlled trialEfficacy outcome
In patients with psoriasis, PTH-treated lesions showed marked improvement in erythema.
In plain wordsIn patients with psoriasis, PTH-treated lesions had less redness.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseLesion erythema
Study
n: not reported in source
Outcome group
Skin and hair · Skin and wound
Studied dose
20 microg per 0.1 g twice daily · topical · 2 monthsAs given in this study (human).
Source sentences
Summary
Psoriatic lesions treated with PTH (1-34) showed marked improvement in scaling, erythema and induration.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifteen adult patients with chronic plaque psoriasis who had failed to respond to at least one standard treatment were enrolled in a randomized double-blinded placebo self-controlled trial. The patients topically applied to a 25-cm2 psoriatic lesion 0.1 g of either Novasome A cream or Novasome A cre…
Report a problemFND-1293224503
04HumanRandomized controlled trialEfficacy outcome
In patients with psoriasis, PTH-treated lesions showed marked improvement in induration.
In plain wordsIn patients with psoriasis, PTH-treated lesions had less skin thickening.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseLesion induration
Study
n: not reported in source
Outcome group
Skin and hair · Skin and wound
Studied dose
20 microg per 0.1 g twice daily · topical · 2 monthsAs given in this study (human).
Source sentences
Summary
Psoriatic lesions treated with PTH (1-34) showed marked improvement in scaling, erythema and induration.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifteen adult patients with chronic plaque psoriasis who had failed to respond to at least one standard treatment were enrolled in a randomized double-blinded placebo self-controlled trial. The patients topically applied to a 25-cm2 psoriatic lesion 0.1 g of either Novasome A cream or Novasome A cre…
Report a problemFND-1293224504
05HumanNon-randomized trialEfficacy outcome
In the open psoriasis trial, PTH improved the Psoriasis Area and Severity Index by 42.6%.
In plain wordsIn patients with psoriasis, the severity index improved during open PTH treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePsoriasis Area and Severity Index
Study
n = 10
Outcome group
Skin and hair · Skin and wound
Studied dose
50 microg per 0.1 g once daily · topicalAs given in this study (human).
Measurements
PASI improvement
42.6%
Open trial
Source sentences
Summary
A Psoriasis Area and Severity Index score analysis of all the patients revealed improvement of 42.6% (P < 0.02).
3 context sentences(design, population, supporting numbers)
Summary · context
Ten patients applied PTH (1-34) (50 microg per 0.1 g) once daily to their psoriatic lesions.
Summary · context
Ten patients topically applied PTH (1-34) on all of their lesions in a stepwise manner.
Summary · context
Fifteen adult patients with chronic plaque psoriasis who had failed to respond to at least one standard treatment were enrolled in a randomized double-blinded placebo self-controlled trial. The patients topically applied to a 25-cm2 psoriatic lesion 0.1 g of either Novasome A cream or Novasome A cre…
Report a problemFND-1293224506
06HumanNon-randomized trialSafety outcome
In psoriasis trials, no patient experienced hypercalcaemia during topical PTH treatment.
In plain wordsIn patients with psoriasis, topical PTH treatment produced no reported high blood calcium.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableHypercalcaemia
Study
n: not reported in source
Outcome group
Adverse events · Endocrine and hormones
Studied dose
Dose not stated · topicalAs given in this study (human).
Source sentences
Summary
None of the patients experienced hypercalcaemia or hypercalciuria or developed any side-effect to the medication.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen adult patients with chronic plaque psoriasis who had failed to respond to at least one standard treatment were enrolled in a randomized double-blinded placebo self-controlled trial.
Summary · context
At the end of the double-blind study, patients were enrolled in an open large area study. Ten patients applied PTH (1-34) (50 microg per 0.1 g) once daily to their psoriatic lesions.
Report a problemFND-1293224507
07HumanNon-randomized trialSafety outcome
In psoriasis trials, no patient experienced hypercalciuria during topical PTH treatment.
In plain wordsIn patients with psoriasis, topical PTH treatment produced no reported high urine calcium.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableHypercalciuria
Study
n: not reported in source
Outcome group
Adverse events · Kidney and urinary
Studied dose
Dose not stated · topicalAs given in this study (human).
Source sentences
Summary
None of the patients experienced hypercalcaemia or hypercalciuria or developed any side-effect to the medication.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen adult patients with chronic plaque psoriasis who had failed to respond to at least one standard treatment were enrolled in a randomized double-blinded placebo self-controlled trial.
Summary · context
At the end of the double-blind study, patients were enrolled in an open large area study. Ten patients applied PTH (1-34) (50 microg per 0.1 g) once daily to their psoriatic lesions.
Report a problemFND-1293224508
08HumanNon-randomized trialSafety outcome
In psoriasis trials, no patient developed a medication side effect during topical PTH treatment.
In plain wordsIn patients with psoriasis, no medication side effects were reported during topical PTH treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableSide effects
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · topicalAs given in this study (human).
Source sentences
Summary
None of the patients experienced hypercalcaemia or hypercalciuria or developed any side-effect to the medication.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen adult patients with chronic plaque psoriasis who had failed to respond to at least one standard treatment were enrolled in a randomized double-blinded placebo self-controlled trial.
Summary · context
At the end of the double-blind study, patients were enrolled in an open large area study. Ten patients applied PTH (1-34) (50 microg per 0.1 g) once daily to their psoriatic lesions.
Report a problemFND-1293224509

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

09LabNot a test of Teriparatide (PTH 1-34) aloneEx vivo tissuePharmacokinetics
In human skin, Novasome A cream enhanced PTH absorption compared with propylene glycol or saline formulations.
In plain wordsIn lab tests, Novasome A cream increased PTH absorption through human skin compared with propylene glycol or saline formulations.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePercutaneous absorption
Study
humann: not reported in source
Human skin
Comparator
Propylene glycol or normal saline formulations
Outcome group
Skin and hair · Skin and wound
Source sentences
Summary
Novasome A cream enhanced the percutaneous absorption of PTH (1-34) in human skin in comparison with formulations in propylene glycol or normal saline.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1293224501

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT00593177

A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis

Manhattan Pharmaceuticalsn = 61Oct 2007 to Jul 2008

Psoriasis Vulgaris

Trial page ClinicalTrials.govUpdated 19 Aug 2008

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.